What is Chardan Capital Markets's price target for NTLA?

Chardan Capital Markets's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $172, from its action on Mar 1, 2022.

What is Chardan Capital Markets's rating on NTLA?

Chardan Capital Markets rates NTLA Buy, a bullish rating, as of Mar 1, 2022.

When did Chardan Capital Markets last change its view on NTLA?

On Mar 1, 2022, Chardan Capital Markets cuts its price target to $172 from $177, keeps Buy.

Analyst firms · Chardan Capital Markets · NTLA

Chardan Capital Markets NTLA price target and rating history

Intellia Therapeutics Inc. (NTLA) · Health Care

Chardan Capital Markets rates Intellia Therapeutics Inc. (NTLA) Buy with a $172 price target, as of its latest action on Mar 1, 2022. It has published 3 rating actions on NTLA since June 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a NTLA price target in the last 12 months, the median target is $8.

Current rating: Buy
Price target: $172
Median target, all firms: $8
Actions on NTLA: 3

Chardan Capital Markets price target on NTLA

Chardan Capital Markets price target on NTLA, each point a stated target, June 2021 to March 2022.

Every Chardan Capital Markets rating on NTLA

Mar 1, 2022
ReiterateChardan Capital Markets cuts its price target to $172 from $177, keeps Buy
Aug 6, 2021
ReiterateChardan Capital Markets raises its price target to $177 from $130, keeps Buy
Jun 28, 2021
ReiterateChardan Capital Markets raises its price target to $130 from $85, keeps Buy

How other firms rate NTLA

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Barclays	Underweight	$8	Oct 6, 2026
Wolfe Research	Underperform	$9	Jul 16, 2026
William Blair	Outperform		Mar 2, 2026
Evercore ISI	In-line	$8	Nov 11, 2025

Questions about Chardan Capital Markets and NTLA

What is Chardan Capital Markets's price target for NTLA?: Chardan Capital Markets's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $172, from its action on Mar 1, 2022.
What is Chardan Capital Markets's rating on NTLA?: Chardan Capital Markets rates NTLA Buy, a bullish rating, as of Mar 1, 2022.
When did Chardan Capital Markets last change its view on NTLA?: On Mar 1, 2022, Chardan Capital Markets cuts its price target to $172 from $177, keeps Buy.
How does Chardan Capital Markets's NTLA target compare with other analysts?: Across 3 firms with a NTLA price target in the last 12 months, the median target is $8.

More NTLA rating histories

All Chardan Capital Markets ratings NTLA news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.